Clinical trial · Interventional
Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial
A Pilot Study of an Individually Tailored, Supervised, Remotely Delivered Exercise Intervention to Improve Physical Function in Survivors of Gastroesophageal Cancer (PRECISE Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial tests an individually tailored, supervised, remote exercise intervention to improve physical function for stage I-III gastroesophageal cancer survivors. Modern treatments for gastroesophageal cancer are effective at treating the cancer but are often aggressive, can be difficult for patients to tolerate, and can lead to significant debilitation and a loss of independence. Exercise is one promising intervention that could improve physical function in patients with gastroesophageal cancer after finishing systemic treatment. Home based exercise interventions in patients with cancer during and after chemotherapy can improve fatigue and function. An individually tailored, supervised, remote exercise intervention may improve physical function for stage I-III gastroesophageal cancer survivors.
Conditions
Conditions (12)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8 | — | UNRESOLVED | — |
| Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8 | — | UNRESOLVED | — |
| Clinical Stage I Gastric Cancer AJCC v8 | — | UNRESOLVED | — |
| Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 | — | UNRESOLVED | — |
| Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | — | UNRESOLVED | — |
| Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 | — | UNRESOLVED | — |
| Clinical Stage II Gastric Cancer AJCC v8 | — | UNRESOLVED | — |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Actigraphy | Other | — | UNRESOLVED |
| Biospecimen Collection | Procedure | — | UNRESOLVED |
| Educational Intervention | Other | — | UNRESOLVED |
| Electronic Health Record Review | Other | — | UNRESOLVED |
| Exercise Intervention | Other | — | UNRESOLVED |
| Internet-Based Intervention | Other | — | UNRESOLVED |
| Physical Performance Testing | Other | — | UNRESOLVED |
| Survey Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Supportive care (Remote exercise intervention)
- description
- Patients receive access to the Moterum application and complete remotely delivered, supervised exercise sessions, over 1 hour, 3 times per week for 8 weeks. Sessions consist of both aerobic and resistance training exercises. Patients also receive written instructions and videos of strengthening exercises. Patients undergo blood sample collection throughout the study.
- interventionNames
- Other: Actigraphy
- Procedure: Biospecimen Collection
- Other: Educational Intervention
- Other: Electronic Health Record Review
- Other: Exercise Intervention
- Other: Internet-Based Intervention
- Other: Physical Performance Testing
- Other: Survey Administration
Primary outcomes (1)
- measure
- Percentage of participants who attend at least 80% of the exercise sessions and complete the post-intervention functional assessment
- timeFrame
- At 8 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults ≥ 18 years old at the start of study treatment * Diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric cancer. Histology can be adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma * Treated with at least one systemic therapy (chemotherapy or immunotherapy) and within 12 months of completing curative intent gastroesophageal cancer (GEC) treatment * Have evidence of physical function impairment, defined as a SPPB score of \< 12) at baseline * Ability to understand English and the willingness to sign a written informed consent document Exclusion Criteria: * Patients with stage I disease who underwent endoscopic resection or surgery alone without perioperative systemic therapy * Patients with stage IV disease or unresectable locally advanced disease taking a palliative treatment approach without a clearly defined end of treatment * Patients currently receiving ongoing systemic therapy for GEC or another malignancy * Patients who are unable to provide informed consent * Any other condition or pre-existing co-morbidity that would, in the Investigator's judgment, contraindicate the participation in the study due to safety concerns with study procedures * Currently participating in another exercise intervention research study seeking to improve functional status, alleviate frailty, muscle strength, exhaustion/fatigue, or cognitive function
References
Publications (0)
Data not yet available